Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
CRNX Analyst Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CRNX Stock 12 Month Forecast
Average Price Target
$72.50
▲(133.04%Upside)
| Highest Price Target$97.00 | Average Price Target$72.50 | Lowest Price Target$36.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$32
Hold
2.86%
Upside
Reiterated
07/19/25
Crinetics Pharmaceuticals has a moderate stock score driven by promising future growth potential from its robust pipeline and strategic advancements. However, significant financial challenges and valuation concerns, including ongoing losses and a negative P/E ratio, pose risks. The mixed technical indicators also reflect uncertainty in the stock's current trend.
JonesTrading
$71
Buy
128.22%
Upside
Reiterated
07/17/25
Citizens JMP
$90
Buy
189.30%
Upside
Reiterated
07/15/25
Leerink Partners
$80
Buy
157.15%
Upside
Reiterated
07/14/25
Goldman Sachs
$36
Hold
15.72%
Upside
Initiated
07/10/25
LifeSci Capital
$82
Buy
163.58%
Upside
Reiterated
07/01/25
H.C. Wainwright
$81
Buy
160.37%
Upside
Reiterated
06/27/25
Citi
$63
Buy
102.51%
Upside
Reiterated
06/26/25
Morgan Stanley
$65
Buy
108.94%
Upside
Reiterated
06/26/25
Piper Sandler
$97
Buy
211.80%
Upside
Reiterated
05/21/25
TD Cowen
―
Buy
―
Reiterated
05/08/25
J.P. Morgan
$57→$53
Buy
70.36%
Upside
Reiterated
03/26/25
Cantor Fitzgerald
$90→$100
Buy
221.44%
Upside
Reiterated
02/28/25
Wolfe Research
―
Hold
―
Initiated
02/03/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$32
Hold
2.86%
Upside
Reiterated
07/19/25
Crinetics Pharmaceuticals has a moderate stock score driven by promising future growth potential from its robust pipeline and strategic advancements. However, significant financial challenges and valuation concerns, including ongoing losses and a negative P/E ratio, pose risks. The mixed technical indicators also reflect uncertainty in the stock's current trend.
JonesTrading
$71
Buy
128.22%
Upside
Reiterated
07/17/25
Citizens JMP
$90
Buy
189.30%
Upside
Reiterated
07/15/25
Leerink Partners
$80
Buy
157.15%
Upside
Reiterated
07/14/25
Goldman Sachs
$36
Hold
15.72%
Upside
Initiated
07/10/25
LifeSci Capital
$82
Buy
163.58%
Upside
Reiterated
07/01/25
H.C. Wainwright
$81
Buy
160.37%
Upside
Reiterated
06/27/25
Citi
$63
Buy
102.51%
Upside
Reiterated
06/26/25
Morgan Stanley
$65
Buy
108.94%
Upside
Reiterated
06/26/25
Piper Sandler
$97
Buy
211.80%
Upside
Reiterated
05/21/25
TD Cowen
―
Buy
―
Reiterated
05/08/25
J.P. Morgan
$57→$53
Buy
70.36%
Upside
Reiterated
03/26/25
Cantor Fitzgerald
$90→$100
Buy
221.44%
Upside
Reiterated
02/28/25
Wolfe Research
―
Hold
―
Initiated
02/03/25
Best Analysts Covering Crinetics Pharmaceuticals
1 Month
xxx
Success Rate
8/12 ratings generated profit
Average Return
+12.70%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +12.70% per trade.
3 Months
xxx
Success Rate
11/12 ratings generated profit
Average Return
+24.05%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 91.67% of your transactions generating a profit, with an average return of +24.05% per trade.
1 Year
Success Rate
13/21 ratings generated profit
Average Return
+33.10%
reiterated a buy rating 24 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +33.10% per trade.
2 Years
xxx
Success Rate
19/30 ratings generated profit
Average Return
+56.34%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.33% of your transactions generating a profit, with an average return of +56.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CRNX Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
20
13
14
17
20
Buy
4
2
1
1
1
Hold
2
1
0
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
16
15
20
24
Each month's total comprises the sum of three months' worth of ratings.
CRNX Financial Forecast
CRNX Stock Forecast FAQ
What is CRNX’s average 12-month price target, according to analysts?
Based on analyst ratings, Crinetics Pharmaceuticals’s 12-month average price target is 72.50.
What is CRNX’s upside potential, based on the analysts’ average price target?
Crinetics Pharmaceuticals has 133.04% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CRNX a Buy, Sell or Hold?
Crinetics Pharmaceuticals has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
What is Crinetics Pharmaceuticals’s price target?
The average price target for Crinetics Pharmaceuticals is 72.50. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $97.00 ,the lowest forecast is $36.00. The average price target represents 133.04% Increase from the current price of $31.11.
The highest analyst price target is $97.00 ,the lowest forecast is $36.00. The average price target represents 133.04% Increase from the current price of $31.11.
What do analysts say about Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of CRNX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.